June 27, 1991
Oral Anticoagulant Drugs
Key Result
Vitamin K-antagonist drugs have seen considerable progress in understanding their mode of action, standardizing anticoagulant measurement, and improving safety with lower degrees of anticoagulation.
PICO
Population
Thromboembolic disorders
Intervention / Comparator
Vitamin K-antagonist drugs (Warfarin)
Abstract
The vitamin K-antagonist drugs were reviewed in the Journal in the early 1970s.1 , 2 Since then, there has been considerable progress in research at both a basic and an applied level. The mode of action of coumarins has been clarified; their role in the management of thromboembolic disorders has been more clearly defined; a system has been developed to standardize the measurement of their anticoagulant effect3; and their safety has been improved for a number of indications without compromising efficacy, through the use of a lower degree of anticoagulation than formerly in North America.4 Warfarin (a 4-hydroxycoumarin compound) is the . . .
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Cite this study
Oates et al. (Thu,) conducted a review in Thromboembolic disorders. Vitamin K-antagonist drugs (Warfarin) was evaluated. Vitamin K-antagonist drugs have seen considerable progress in understanding their mode of action, standardizing anticoagulant measurement, and improving safety with lower degrees of anticoagulation.
synapsesocial.com/papers/6a0ea6d306ecbe833447a856 — DOI: https://doi.org/10.1056/nejm199106273242606
Authors
John A. Oates
General Cardiology
A
Alastair J.J. Wood
Northwestern University
Jack Hirsh
Vascular Medicine
Journals
New England Journal of Medicine
Actions
Institutions
McMaster University
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...